Vantage Oncology, LLC and Vantage Oncology Finance Co. Announce Extension of Early Tender Time for Tender Offer for 2017 Notes

MANHATTAN BEACH, Calif., March 24, 2016 /PRNewswire/ -- Vantage Oncology, LLC (the "Company") and Vantage Oncology Finance Co. (together with the Company, the "Issuers") today announced that they have extended the early tender time for their previously announced cash tender offer (the "Offer") for any and all of the outstanding $300.0 million aggregate principal amount of their 9.500% Senior Secured Notes due 2017 (the "Notes"), from 5:00 p.m., New York City time, on Friday, March 25, 2016, to 5:00 p.m., New York City time, on Monday, March 28, 2016 (as so extended, the "Early Tender Time"), unless further extended.  The previously announced Withdrawal Deadline for the Offer of 5:00 p.m., New York City time, on March 25, 2016, remains unchanged.  All other terms, provisions and conditions of the Offer will remain in full force and effect.  Such terms, provisions and conditions are set forth in the Issuers' Offer to Purchase and Consent Solicitation Statement, dated March 11, 2016, and the related letter of transmittal (the "Offer Documents"), copies of which were previously distributed to eligible holders of the Notes ("Holders"). All capitalized terms in this press release that are used but not otherwise defined have the meanings set forth in the Offer Documents.

The Offer is scheduled to expire at 12:00 midnight, New York City time, at the end of April 8, 2016 (unless extended) (the "Expiration Time").

An Early Settlement Date for Notes tendered at or prior to the Early Tender Time is expected to occur on or about April 1, 2016. The Final Settlement Date for Notes tendered after the Early Tender Time and at or prior to the Expiration Time, and accepted by the Issuers for purchase in the Offer is expected to occur on or about April 11, 2016, unless extended by the Issuers in their sole discretion.

Wells Fargo Bank, National Association is acting as tender agent for the Offer and can be contacted at (800) 344-5128, option 0. Copies of the Offer Documents and other related documents may be obtained from the Company by contacting (310) 335-4000.

No recommendation is made as to whether Holders of the Notes should tender their Notes or give their consent. Holders of Notes must make their own decisions as to whether to tender their Notes, and if they decide to do so, the principal amount of the Notes to tender. Holders of the Notes should read carefully the Offer Documents and related materials before any decision is made with respect to the Offer.

This announcement shall not constitute an offer to purchase or a solicitation of an offer to sell any securities, nor shall there be any purchase of Notes in any state or jurisdiction in which such offer, solicitation or purchase would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Offer is being made only through, and subject to the terms and conditions set forth in, the Offer Documents and related materials.

About Vantage

Founded in October 2002, Manhattan Beach, California-based Vantage Oncology, LLC is a leading national provider of radiation oncology, medical oncology and other value-based integrated cancer care services. The company's founding principles were to address the growing need among cancer patients, hospitals and physicians for accessible and advanced cancer treatments. Vantage currently operates over 50 treatment facilities in 13 states. For more information about Vantage, visit www.vantageoncology.com.

Cautionary Statement on Forward-Looking Statements

Information in this release may involve outlook, expectations, beliefs, plans, intentions, strategies or other statements regarding the future, which are forward-looking statements. These forward-looking statements involve risks and uncertainties. All forward-looking statements included in this release are based upon information available to us as of the date of the release, and we assume no obligation to update any such forward-looking statements. The statements in this release are not guarantees of future performance, and actual results could differ materially from current expectations. Numerous factors could cause or contribute to such differences. Please refer to "Risk Factors" and "Cautionary Statements Regarding Forward-Looking Statements" in the Issuers' Annual Report for the fiscal year ended December 31, 2014.

SOURCE Vantage Oncology, LLC